Agios Pharmaceuticals, Inc.
General ticker "AGIO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.1B (TTM average)
Agios Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 36.8%.
Estimated limits based on current volatility of 1.3%: low 27.01$, high 28.31$
Factors to consider:
- Total employees count: 488 as of 2024
- Top business risk factors: Product development delays, Regulatory and compliance, Public health crises, Operational and conduct risks, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [23.45$, 52.10$]
- 2025-12-31 to 2026-12-31 estimated range: [19.12$, 43.44$]
Financial Metrics affecting the AGIO estimates:
- Negative: with PPE of -51.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -19.70 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Positive: Return on assets ratio (scaled to [-100,100]) of 28.83 > 6.04
- Positive: Shareholder equity ratio, % of 92.65 > 63.39
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry earnings per price (median), % of -16.34 <= 0
Short-term AGIO quotes
Long-term AGIO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $14.24MM | $26.82MM | $36.50MM |
| Operating Expenses | $403.29MM | $418.31MM | $462.24MM |
| Operating Income | $-389.05MM | $-391.49MM | $-425.74MM |
| Non-Operating Income | $157.25MM | $39.40MM | $1,143.71MM |
| R&D Expense | $279.91MM | $295.53MM | $301.29MM |
| Income(Loss) | $-231.80MM | $-352.09MM | $717.97MM |
| Taxes | $0.00MM | $0.00MM | $44.24MM |
| Profit(Loss)* | $-231.80MM | $-352.09MM | $673.73MM |
| Stockholders Equity | $1,100.81MM | $811.02MM | $1,540.96MM |
| Inventory | $8.49MM | $19.08MM | $27.62MM |
| Assets | $1,238.72MM | $937.12MM | $1,663.20MM |
| Operating Cash Flow | $-309.48MM | $-296.06MM | $-389.84MM |
| Capital expenditure | $4.88MM | $1.00MM | $1.69MM |
| Investing Cash Flow | $243.26MM | $239.57MM | $363.44MM |
| Financing Cash Flow | $2.35MM | $5.43MM | $14.44MM |
| Earnings Per Share** | $-4.23 | $-6.33 | $11.86 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.